Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients

Journal of Medical Economics

Volumn 4, Issue 99-113, 2001, Pages 99-113

  Lloyd, A C ^a   Anderson, P M ^a   Quinlan, D J ^a   Bearne, A ^a  

^a Fourth Hurdle Consulting Ltd   (United Kingdom)

Author keywords

Cost effectiveness; Enoxaparin; Heparin; Medical; Prophylaxis; Thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0034943798     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200104099113     Document Type: Article

References (36)

1. Risk of and prophylaxis for thromboembolism in hospital patients
2. Prevention of venous thromboembolism: European consensus statement
3. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
4. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery: Clinical and economic considerations
5. Low molecular weight versus unfractionated heparin: A clinical and economic appraisal
6. Efficacy and cost of low molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty
7. The changing pattern of venous thromboembolic disease
8. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism in hospital patients. The Worcester DVT study
9. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment
10. A fatal pulmonary embolism in hospitalised medical patients
11. Prevention of venous thromboembolism
12. Prevention of venous thromboembolism: International consensus statement (guidelines according to clinical evidence)
13. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
14. Low molecular weight heparins versus standard heparins in general and orthopaedic surgery: A meta analysis
15. Low molecular weight heparin in prevention of perioperative thrombosis
16. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: A meta-analysis of randomised clinical trials
17. Prevention of venous thromboembolism
18. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep-vein thrombosis (DVT) in elective hip surgery
19. A cost effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopaedic surgery
20. Prevention of venous thromboembolism in patients hospitalized for more than 24 hours in a medical ward: Proposed indications for low molecular weight heparins
21. Cost of long-term complications of deep vein thrombosis of the lower extremities: An analysis of a defined patient population in Sweden
22. British National Formulary (39)
23. Heparin administration using prefilled syringes or ampoules: A comparative cost-effectiveness study
24. A non-invasive diagnostic strategy including spiral computed tomography in patients with suspected pulmonary embolism
25. Spiral computed tomography is comparable to angiography for the diagnosis of pulmonary embolism
26. Survey on the use of pulmonary scintography, spiral CT and conventional pulmonary angiography for suspected pulmonary embolism in the British Isles
27. Guidelines on diagnosis and management of acute pulmonary embolism
28. The venous thrombotic risk in nonsurgical patients; epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin)
29. Study to compare the efficacy and safety of the LMWH enoxaparin and standard heparin in the prevention of thromboembolic events in medical patients with cardiopulmonary diseases
30. Low molecular weight heparins
31. Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis